ClinicalTrials.gg
RecruitingNCT07206602Updated Feb 18, 2026

AI-Guided Left Bundle Branch Area Pacing

An interventional study of AI-assisted Left Bundle Branch Area Pacing and Left Bundle Branch Area Pacing in Heart Failure, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Heart Failure by Mayo Clinic — 16 open to participants now, 17 under way, none of them phase 3. Heart Failure · Mayo Clinic.

Planned enrollment
6th of 48
224 · median 36
Started
2026
with 4 others
No phase
24 of 69
6 open now
Primary completion
2027-11
later than 9 of 16 live
Registered
66th of 69
by date

Among the 69 studies in Heart Failure by Mayo Clinic, this one is the 6th largest by planned enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2026, is one of 24 with no phase, reaches primary completion later than 9 of the 16 other live ones, and was the 66th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 69 studies in Heart Failure by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Heart Failure by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effectiveness of AI-guided LBBAP versus conventional LBBAP (not AI-guided) in improving CRT response rates and clinical outcomes.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 years or older.
  • (LVEF): \<50% within 6 months prior to enrollment.
  • QRS Duration: Resting QRS duration ≥ 130 ms on OR anticipated right ventricular pacing > 40% OR device in place with right ventricular pacing > 40% within 6 months prior to enrollment.
  • Medical Therapy: Optimized on guideline-directed medical therapy for heart failure.
  • AI-ECG probability of low LVEF: >0.5

Exclusion criteria

Exclusion Criteria

  • Age less than 18 years old
  • Inability to follow-up
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
224 participants (estimated)

Study arms

  • Experimental
    AI-guided

    Device: AI-assisted Left Bundle Branch Area Pacing

  • Active comparator
    Control

    Procedure: Left Bundle Branch Area Pacing

Interventions

  • DeviceAI-assisted Left Bundle Branch Area Pacing

    Patients will undergo a Left Bundle Branch Area Pacing (LBBAP) procedure using AI assisted technology

  • ProcedureLeft Bundle Branch Area Pacing

    Patients will undergo a Left Bundle Branch Area Pacing (LBBAP) procedure

06

What researchers measure

Primary outcomes

  1. CRT response rate

    CRT response is defined as an absolute increase of \>5% in left ventricular ejection fraction (LVEF) after 6 months of CRT

    Time frame: Baseline, 6 months

Secondary outcomes

  1. NYHA (New York Heart Association) Class

    The New York Heart Association (NYHA) classification will be assessed using the NYHA questionnaire, which evaluates the extent of physical limitations caused by heart failure. This system categorizes patients into one of four classes, with higher classes indicating more severe functional impairment.

    Time frame: Baseline, 6 months

  2. Number of Hospitalizations

    Number of Hospitalizations will be determined by the number of participants that are hospitalized for heart failure.

    Time frame: 6 months

  3. Number of Deaths

    Number of patient deaths by any cause

    Time frame: 6 months

  4. Left Ventricular Linear Dimensions

    Left Ventricular Linear Dimensions will be measured by an echocardiogram. A lower value indicates better cardiac function.

    Time frame: Baseline, 3 months

  5. Left Ventricular Linear Volume

    Left Ventricular Linear Volume will be measured by an echocardiogram. A lower value indicates better cardiac function.

    Time frame: Baseline, 3 months

  6. Procedural success: LBBAP-conventional arm

    LBBAP is considered successful if unipolar paced QRS morphology demonstrated a Qr or qR morphology in lead V1 along with any 1 of the following criteria: * Left bundle branch potential * Transition to selective left bundle branch capture or left ventricular septal capture during threshold testing or programmed stimulation * R-wave peak time \<90 ms in V5-V6 * V6-V1 interpeak interval \>44 ms

    Time frame: Baseline

  7. Procedural success: AI-LBBAP arm

    Procedural success is defined as improvement in the AI-ECG predicted likelihood of having a low LVEF from greater than 0.5 at baseline to less than 0.5 after LBBAP.

    Time frame: Baseline

  8. Fluoroscopy time

    Fluoroscopy time will be determined by the amount of time that fluoroscopy is used to guide the left bundle branch area pacing (an average of 30 minutes)

    Time frame: Baseline, Approximately 30 minutes

  9. Total procedure time

    Total procedure time will be determined by the start of the LBBAP procedure until completion (an average of 2 hours)

    Time frame: Baseline, Approximately 1-2 hours

  10. Lead pacing thresholds

    Lead pacing thresholds will be measured in Voltage at millisecond.

    Time frame: Baseline

  11. Impedance

    Impedance will be measured in Ohms.

    Time frame: Baseline

  12. Sensing Parameters

    Sensing Parameters will be measured in mV (milliVolts)

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2027, 22 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 22 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 3, 2025
StartActual
Jan 23, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07206602
Lead sponsor
Mayo Clinic
Responsible party
Fatima M. Ezzeddine (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 3, 2025
Start date
Jan 23, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Joseph Abdel Messih
Contact
mansour.joseph@mayo.edu
507-422-3967
Fatima Ezzeddine
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion